Compare · ILMN vs KEQU
ILMN vs KEQU
Side-by-side comparison of Illumina Inc. (ILMN) and Kewaunee Scientific Corporation (KEQU): market cap, price performance, sector, and recent activity on the wire.
Summary
- ILMN operates in Health Care, while KEQU operates in Industrials - the two are in different parts of the market.
- ILMN is the larger of the two at $28.24B, about 258.2x KEQU ($109.4M).
- Over the past year, ILMN is up 97.0% and KEQU is down 36.5% - ILMN leads by 133.5 points.
- KEQU has been more active in the news (8 items in the past 4 weeks vs 5 for ILMN).
- ILMN has more recent analyst coverage (25 ratings vs 0 for KEQU).
- Company
- Illumina Inc.
- Kewaunee Scientific Corporation
- Price
- $186.76-1.85%
- $36.47-1.45%
- Market cap
- $28.24B
- $109.4M
- 1M return
- +13.80%
- -1.29%
- 1Y return
- +97.03%
- -36.52%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- News (4w)
- 5
- 8
- Recent ratings
- 25
- 0
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Kewaunee Scientific Corporation
Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. It operates in two segments, Domestic and International. The company's products include steel, wood, laminate furniture, fume hoods, biological safety cabinets, laminar flow and ductless hoods, adaptable modular and column systems, moveable workstations and carts, epoxy resin worksurfaces, sinks, and accessories and related design services. Its laboratory products are used in chemistry, physics, biology, and other general science laboratories in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, government, and health care markets; technical products are used in facilities manufacturing computers and light electronics and by users of computer and networking furniture; and laminate caseworks that are used in educational, healthcare, and industrial applications. The company sells its products primarily through dealers, commissioned agents, and a national distributor, as well as through competitive bids submitted by the company and its subsidiaries in Singapore, India, and China. Kewaunee Scientific Corporation was founded in 1906 and is headquartered in Statesville, North Carolina.
Latest ILMN
- Illumina expands Billion Cell Atlas program with new AI drug developers
- Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
- Director Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)
- Director Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)
- Bernstein resumed coverage on Illumina with a new price target
- Chief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)
- Director Skovronsky Daniel was granted 1,674 shares (SEC Form 4)
- SEC Form 3 filed by new insider Skovronsky Daniel
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Latest KEQU
- SEC Form DEFA14A filed by Kewaunee Scientific Corporation
- SEC Form DEF 14A filed by Kewaunee Scientific Corporation
- SVP, People & Culture Phillips Elizabeth D converted options into 6,656 shares, returned $181,069 worth of shares to the company (4,995 units at $36.25) and covered exercise/tax liability with 793 shares, increasing direct ownership by 11% to 9,116 units (SEC Form 4)
- SVP, IT & Engineering Ranade Mandar converted options into 7,227 shares, returned $65,250 worth of shares to the company (1,800 units at $36.25) and covered exercise/tax liability with 1,877 shares, increasing direct ownership by 28% to 16,215 units (SEC Form 4)
- SVP, Sales & Marketing Dev Noble Ryan S. returned $108,750 worth of shares to the company (3,000 units at $36.25), covered exercise/tax liability with 1,809 shares and converted options into 7,206 shares, increasing direct ownership by 17% to 16,240 units (SEC Form 4)
- SVP, Manufacturing Operations Batdorff Douglas J. converted options into 7,451 shares, returned $203,326 worth of shares to the company (5,609 units at $36.25) and covered exercise/tax liability with 851 shares, increasing direct ownership by 14% to 8,170 units (SEC Form 4)
- Chief Financial Officer Gardner Donald T. Iii converted options into 21,265 shares, returned $435,000 worth of shares to the company (12,000 units at $36.25) and covered exercise/tax liability with 4,027 shares, increasing direct ownership by 55% to 14,802 units (SEC Form 4)
- President & CEO Hull Thomas David Iii converted options into 54,388 shares, returned $616,250 worth of shares to the company (17,000 units at $36.25) and covered exercise/tax liability with 16,243 shares, increasing direct ownership by 64% to 54,145 units (SEC Form 4)
- SEC Form 10-K filed by Kewaunee Scientific Corporation
- SEC Form 4 filed by SVP, People & Culture Phillips Elizabeth D